“Novartis has been and is alongside all the players in the ecosystem to guarantee the possibility of carrying out neonatal screening, which represents a unique opportunity to impact the future of the lives of these little children, precisely because a diagnosis in the first days of life of the child allows us to diagnose “spinal muscular atrophy (Sma)” and intervene in an early, pre-symptomatic phase, improving clinical outcomes. This was stated by Roberta Rondena, Country value & access head of Novartis, on the occasion of the press conference in which the pharmaceutical company announced Aifa's green light to the extension of the reimbursement criteria for onasemnogene abeparvovec, the first gene therapy approved in Italy for the treatment of the (Sma). Already approved in 2021 for form 1, it is now also available for children with SMA type 2.
#Rare #diseases #Rondena #Novartis #Neonatal #screening #unique #opportunity #early #diagnosis
